<DOC>
	<DOCNO>NCT02667561</DOCNO>
	<brief_summary>This Phase I , open-label , parallel trial evaluate Pharmacokinetics , Pharmacodynamics Safety Testosterone gel 1 % topic usage post-menopausal woman , 28 day</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodinamic Safety Testosterone Gel 1 %</brief_title>
	<detailed_description>This Phase I , open-label , parallel trial evaluate Pharmacokinetics , Pharmacodynamics Safety Testosterone gel 1 % topic usage post-menopausal woman , Study participant receive investigational product 28 consecutive day , daily , per follow allocation : 2.2 mg , 4.4 mg. 8.8 mg placebo .</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Female subject age ≥ 42 year ≤ 65 year , postmenopausal period least 1 year active sexual life ; Serum testosterone level &lt; 33 ng/mL ; Folliclestimulating hormone ( FSH ) level &gt; 22 mU/mL ; Absence significant disease , physician 's discretion , could impact subject 's participation trial , accord protocol requirement , study evaluation : medical history , blood pressure heart rate measurement , physical examination complimentary laboratory test ; Ability understand nature objective trial , include risk adverse event , shall confirm Informed Consent Form signature . Screening laboratory test result present clinically relevant deviation , investigator discretion , prevent subject participate trial due possible risk ; Drugs addiction , include alcohol ; Treatment drug know wellestablished toxic potential major organ , within 3 month trial , ; Participation experimental research administration experimental drug within six month initiation trial ; Pregnancy , labor miscarriage last 12 week antecipated date study treatment start ; Any condition , accord investigator 's best judgement , prevents subject participate trial .</criteria>
	<gender>Female</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>